Monthly News Roundup: November 2017

Welcome to the Medrio Monthly News Roundup, in which we brief you on a sample of events and developments taking place around the industry. This recurring update functions on popular demand – the stories in this post come from the articles in our social media feeds that garnered the most attention from our readers and followers. Your likes, clicks, and retweets decide which stories make it beyond your newsfeed and onto our blog.

This month, we bring you insights into the future of pragmatic trials, findings on salaries and turnover in clinical monitoring, and research data on growth in the biopharma sector. Take a look, and tune in for the next roundup in a month!

1. Generating a rich source of real-world data through pragmatic trials

Designed to evaluate the effectiveness of treatment interventions in routine general practice, pragmatic trials provide data that can be generalized and applied in real-world settings. As such, they’re an increasingly valuable source of real-world data (RWD). An article we shared describes how electronic data capture can support pragmatic trials by enabling patients to use their own devices, known as a “Bring Your Own Device” (BYOD) approach.

2. Clinical monitoring salaries and turnover continue to rise

Data from a 2017 survey of 28 public and private CROs showed that turnover in the clinical monitoring job function outside the U.S. increased 40 percent last year; in the U.S., the increase was only 2.7 percent. The summary of the survey data also showed that salaries for these positions increased by an average of 8.3 percent, which can be partly attributed to the increasing number of trials and the shortage of qualified professionals.

3. World’s top 20 biopharma companies double market valuations

A new report from investment bankers at Torreya shows that over the past six years, the market valuations of the top 20 biopharma companies have almost doubled, from $1.45 trillion to close to $3 trillion. The story we shared notes that biologics in general, and rare disease biologics in particular, will continue to be standouts for the growth companies in the industry, and China will continue to be a leader in growth.

That’s all for this roundup! We’ll have three more stories for you next month. In the meantime, check out this blog every week for new insights into EDC and clinical research.

| |

Recent Posts